CD47 functionalized exosomes loaded with anti-KRAS G12D are promising delivery platforms to silence KRAS G12D expression and reduce pancreatic tumor burden exclusively in G12D-mutated KRAS-harbored cancerous pancreatic cells. Here, KRAS is linked to pancreatic neoplasm.